Author: Katrina Freeman

  • The United States’ Response to HIV/AIDS

    The United States’ Response to HIV/AIDS

    This brief was originally published by Katrina Freeman on October 7, 2021. It was updated and republished by Pamela Pamela Nwakakwa on June 23, 2022.

    Introduction

    Across the world, approximately 38 million people are living with Human Immunodeficiency Virus (HIV). HIV is the virus which causes Acquired Immunodeficiency Syndrome (AIDS). It is spread through bodily fluids, which enter the bloodstream through a mucous membrane, open cuts or sores, or by direct injection. The most common ways to contract HIV are through: 

    1. Participating in vaginal or anal sex with someone who has HIV without using a condom or taking medicines to prevent or treat HIV.
    2. Sharing injection drug equipment, such as needles, with someone who has HIV.

    Newborns can contract HIV if their mother is HIV positive through breastfeeding, but this is preventable through early intervention

    “HIV can affect anyone regardless of sexual orientation, race, ethnicity, gender, age, or where they live. However, certain groups of people in the United States are more likely to get HIV than others because of particular factors, including the communities in which they live, what subpopulations they belong to, and their risk behaviors.”—HIV.gov

    While HIV/AIDS was once considered a death sentence, medical advances such as ART (anti-retroviral treatment) and PrEP (pre-exposure prophylaxis) have allowed people with the virus to live long lives. Access to these medications are limited, and in some cases the stigma associated with HIV can prevent people from seeking more information or treatment, even if it is available. 

    US Response to Global HIV/AIDS

    The United States funds HIV/AIDS prevention and treatment across the world. The US government donated billions of dollars to the Global Fund, funded PEPFAR programs, and worked alongside UNAIDS to stop the spread of HIV. 

    • The Global Fund is a multilateral partnership between governments, the private sector, and NGOS designed to end the AIDS, tuberculosis and malaria epidemics. The Fund allocates resources to local organizations combating these diseases. Since its founding in 2002, the United States has been the largest donor, contributing $17.6 billion. The United States has also shaped its policies as a member of the Global Fund’s Board. The Global Fund also works hand-in-hand with the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR).
    • PEPFAR: President George W. Bush announced the creation of The U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) in 2003, and it was signed into law with bipartisan support. At the time, PEPFAR was the the “largest commitment by any nation to address a single disease in history” and has allocated “$85 billion in the global HIV/AIDS response, saving over 20 million lives, preventing millions of HIV infections, and achieving HIV/AIDS epidemic control in more than 50 countries around the world.” PEPFAR became the center for the American response to AIDS in Sub-Saharan Africa.

    The Bush Administration hoped PEPFAR would be the medical version of the Marshall Plan, in terms of its scope and impact. “Localization” or shifting decision making powers and implementation away from the United States and towards local leaders and individuals, has been a goal for the organization. Local ownership is considered critical to meet global health and development goals, but there are implementation challenges which have hindered progress. 

    PEPFAR has been reauthorized through three different Administration’s and has become a cornerstone of American global health policy. The original program worked with 15 countries, and the program has expanded to include 60 countries in 2021.

    • UNAIDS: 90-90-90 Initiative: the United States also worked alongside UNAIDS to implement their 90-90-90 initiative. This initiative includes a focus on viral suppression because viral suppression means that a person does not spread the virus. This is key to ending the epidemic. By 2020 this initiative set a goal where: 
    1. 90% of all people living with HIV know their HIV status.
    2. 90% of all people with diagnosed HIV infection receive sustained antiretroviral therapy.
    3. 90% of all people receiving antiretroviral therapy have viral suppression. 

    As of the end of 2020, UNAIDS did not meet its goal. UNAIDS reports that in 2020, of all people with HIV worldwide:

    1. 84% knew their HIV status
    2. 73% were accessing ART
    3. 66% were virally suppressed

    US Response to Domestic HIV/AIDS

    In the United States, new HIV infections are highly concentrated among men who have sex with men; minorities, especially African Americans, Hispanics/Latinos, and American Indians and Alaska Natives; and those who live in the southern United States. Social determinants of health and stigma against the LGBT community and drug users can impede access to care. A key tenant to ending HIV is ensuring that patients know their status and have access to both ART and PrEP to ensure they do not spread HIV to their partners.

    • Ending the HIV Epidemic in the US (EHE): this program is the coordinating body for the American government’s cross-agency response to domestic HIV transmission. It aims to “reduce the number of new HIV infections in the United States by 75% by 2025, and then by at least 90% by 2030.” The HHS Office of the Assistant Secretary for Health is coordinating this response as well as the following agencies, who are working together to reduce domestic HIV infections.
    • Centers for Disease Control and Prevention (CDC)- CDC is working with local and state governments, federal partners, communities, people with HIV and people at risk of getting HIV in order to increase the use of EHE’s strategies
    • Health Resources and Services Administration (HRSA)-HRSA’s Health Center Program and Ryan White HIV/AIDS program play an important role in carrying out EHE’s initiative through funding and providing HIV/AIDS services
    • Indian Health Service (IHS)-IHS concentrates its EHE efforts on organizing and promoting HIV prevention and treatment activities in the communities that are most affected as part of an extensive public health approach
    • National Institutes of Health (NIH)-NIH supports implementation science research done with community partners in EHE jurisdictions to decide what is the best way to use the very effective tools that are already available to deal with HIV
    • Office of the HHS Assistant Secretary for Health (OASH)- OASH provides project management and coordination as a whole and keeps track of progress and delivers information through HIV.gov
    • Substance Abuse and Mental Health Services Administration (SAMHSA)- SAMHSA is using its knowledge to address the intersection of substance use disorders and HIV in order to make sure that the right behavioral health interventions get implemented as part of EHE’s goal

    The Ending the HIV Epidemic initiative focuses on four key strategies that, implemented together, can end the HIV epidemic in the U.S:  Diagnose, Treat, Prevent, and Respond.

    Source: HIV.gov

    The CDC writes: 

    “Our nation faces an unprecedented opportunity once thought impossible. The most powerful HIV prevention and treatment tools in history are now available. Areas where HIV transmission is occurring most rapidly can also be identified. By deploying those tools swiftly and to the greatest effect, the HIV epidemic in America can end.” 

  • Maternal Mortality in the United States

    Maternal Mortality in the United States

    The International Classification of Diseases (ICD-10) defines maternal death as “[the] death of a woman while pregnant or within 42 days of the end of pregnancy from any cause related to or aggravated by the pregnancy or its management, but not from accidental or incidental causes.” Maternal Mortality is a global issue; around the world every minute a woman dies during labor or delivery. According to the World Health Organization, two regions, sub-Saharan Africa and South Asia, account for 86% of maternal deaths worldwide. The United States is an outlier whose maternal mortality rate (MMR) is high compared with other developed countries. 

    Amnesty International released a report in 2010 which explained that global maternal mortality was down 34% (1990-2008) but “the US was among just 23 countries to see an increase in maternal mortality” during that time. In the United States, 18 women die per 100,000 live births—a ratio more than double that of most other high-income countries. In addition, women of color at all income levels are 3 to 4 times more likely to die from childbirth-related complications than white women.

    The literature points to various reasons why the United States has the highest MMR in the developed world. But it focuses specifically on:  

    1. Shortcomings of the US healthcare system.
    2. Implicit racial bias in the medical field which results in a higher maternal mortality rate for BIPOC women in the United States. 

    The American Healthcare System

    American citizens have vastly different experiences with healthcare depending on which state they live in. Some states expanded Medicare through the Affordable Care Act while others opted for a more limited public health program. Abortion policy also varies by state, with states permitting it at different stages in pregnancy and at clinics versus hospitals.

    Low income women who rely on Medicaid face several obstacles in receiving care. In 2019, 20% of obstetricians and gynecologists would not accept new Medicaid patients because of low reimbursement rates and bureaucratic delays. Postpartum care is not covered beyond sixty days of giving birth, and complications can arise up to a year after giving birth. Medicaid provided coverage for 43% of births in the US in 2018, disproportionately covering young women, women of color, and those in rural communities.

    Reducing legal access to family planning services can lead to increased maternal mortality. When abortion is limited, women are more likely to turn to unsafe abortion methods which create a higher risk of maternal death or lifelong health complications. Unsafe abortions are the cause of 13% of maternal deaths globally. 

    Implicit Health Provider Bias

    Louisiana is the state with the highest MMR in the country with 58.1 deaths per 100,000 births. In Louisiana, “59% of black maternal deaths are preventable, compared to 9% of white maternal deaths.” This is the result of both the challenges discussed above, as well as implicit bias in healthcare providers. Healthcare providers frequently hold false beliefs about black people’s pain tolerances, which influence the pain treatment they are prescribed. In addition, black mothers often find that they are not listened to or believed while reporting symptoms, and are pressured into health decisions they don’t feel are in their own or their unborn child’s best interests.

  • The COVAX Initiative

    The COVAX Initiative

    Introduction

    COVID-19 is a rapidly transmissible virus which has shut down the global economy for the past 15 months. In the past six months, vaccine production and distribution has ramped up, but vaccine nationalism—the hoarding of vaccines by countries for their own populations—is threatening to prolong the pandemic for several years. The COVAX Initiative seeks to close this vaccination gap by distributing vaccines to low and middle income countries who otherwise wouldn’t have access to them—an essential step to end the acute stage of the pandemic.

    Wealth inequality is the root of the current global vaccine access disparity. As of March 2020, “High-income countries, representing just a fifth of the global adult population (~20%), have purchased more than half (~54%) of all vaccine doses.” 

    As shown by this figure from the Kaiser Family Foundation, high income countries have enough doses to fully vaccinate their adult populations twice over, while lower income countries can only vaccinate around a quarter of their population. This poses risks for the spread of global variants, as well as a slower global economic recovery. 

    Countries hoard vaccines because they are prioritizing domestic economic recovery and aim to reach herd immunity (with 70% of their citizens vaccinated) within their borders. However, this ideology could end up hurting them more than helping them as variants mutate among the unvaccinated and spread as countries ease lockdowns. This would hinder public health progress and slow economic recovery. Therefore, the COVAX initiative is essential to combat vaccine nationalism by distributing vaccines to low and middle income countries which do not have the same ability to purchase vaccines in bulk.  

    The COVAX Initiative

    The COVID-19 Vaccines Global Access (COVAX) Initiative is an international partnership led by the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance, and the World Health Organization (WHO) to close the vaccination gap between high income countries (HICs) and lower-middle income countries (LMICS). It fulfills the vaccine pillar of the Access to COVID-19 Tools (ACT) Accelerator, which was created in April 2020 to ensure that all countries, regardless of GDP, would have access to needed COVID-19 response resources.

    COVAX seeks to achieve: 

    1. Doses for at least 20% of countries’ populations
    2. Diverse and actively managed portfolio of vaccines
    3. Vaccines delivered as soon as they are available
    4. End the acute phase of the pandemic
    5. Rebuild economies

    COVAX uses international infrastructure to coordinate equitable vaccine distribution and relies on multiple actors in multiple sectors in order to reduce gaps in vaccination coverage. COVAX aims to provide 2 billion COVID-19 vaccines to the most vulnerable citizens in all participating countries through the COVAX Facility, which is a “global risk-sharing mechanism for pooled procurement and equitable distribution of COVID-19 vaccines.” This initiative seeks to combat vaccine nationalism by recognizing that no country or single population will be protected from the virus if populations in low and middle income countries remain unvaccinated. 

    COVAX and US Policy

    Changes in U.S. administrative policies on COVAX reflect different ideologies about the United States’ role on the world stage. The Trump Administration did not join or support the COVAX initiative while in office. However, the Biden Administration is now a vocal supporter of the program and has pledged $4 billion dollars to COVAX. They have also supported waiving intellectual property patents on COVID-19 vaccines. This is consistent with the Administration’s foreign policy strategy of rebuilding alliances and repositioning the U.S. on the world stage as a global leader. 

    Criticisms and Critiques 

    While COVAX is certainly an essential step in the right direction, many organizations feel it is not effectively meeting the needs of the moment. The People’s Vaccine Alliance argues that the COVID-19 vaccines must be seen as a public good and readily available to all those in need, and that COVAX is not the right tool to enable this paradigm shift. These concerns reflect a disconnect between the profit motive of vaccine manufacturers and the imperative to vaccinate as many high risk individuals as possible. In addition, some feel that vaccine hoarding is justified because governments must put the lives of their own citizens before those in other countries. While this does not explain hoarding enough vaccines to vaccinate citizens twice over, it is a main reason why not all countries are ready to give away a portion of their domestic vaccine supply.

  • Katrina Freeman, George Washington University

    Katrina Freeman, George Washington University

    Linkedin

    Katrina Freeman is a Senior at George Washington University, completing a major in International Affairs and minors in Public Health and Public Policy. She has worked at anti-poverty non-profits in Washington DC and is interested in the ways inequity creates public health challenges that can be addressed through policy.